Kidney CancerPODRACINGNCT06536439
Planning Operative Strategy Using a Digital Renal Artery Clamping Tool
A study testing Pre-operative explanation of the procedure (DIPLANN + CT), Pre-operative surgical planning (DIPLANN + CT) and RAPN (DIPLANN + CT) in people with Kidney Cancer and Kidney Neoplasms, run by University Hospital, Ghent at 5 sites in Belgium.
Trial summary
A proposed new tool ('DIPLANN-tool' - Digital Planning in Nephrectomy) for predicting kidney perfusion zones on a segmented 3D model during robot-assisted partial nephrectomy (RAPN) for localized renal cancer demonstrated high accuracy when planning selective clamping (SC) for RAPN. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Kidney Cancer, Kidney Neoplasms, Kidney Diseases
- What is being tested?
- Pre-operative explanation of the procedure (DIPLANN + CT), Pre-operative surgical planning (DIPLANN + CT) and RAPN (DIPLANN + CT)
- Type of treatment
- Medical device, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 235 participants
- Where
- 5 sitesBelgium
- Study dates
- 27 Jun 2024to 1 Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- aged 18 years or above
- cT1-2 N0 M0 renal mass
- planned to undergo RAPN
- multiphase CT scan with arterial phase available
- voluntary given and written informed consent
- sufficient in at least one of the study languages: Dutch, English, French
- For the primary objective, SC needs to be deemed possible either according to the DIPLANN-tool in combination with conventional CT imaging or according to conventional CT imaging only, as assessed by an independent surgeon (between inclusion and randomization) who will not be involved in the RAPN surgical procedure, in order to be included in the analysis set. On the DIPLANN tool, SC is deemed feasible if >= 90% tumor ischemia and <= 70% renal parenchyma ischemia can be achieved. If these criteria are met, but it is technically or anatomically not feasible according to the independent surgeon to perform SC, he can deviate from these criteria and thus claim SC is not deemed possible. The results for the total population (patients in which SC is deemed possible AND impossible pre-operatively by an independent surgeon) will also be analyzed as a secondary objective.
Who cannot join
- > 3 ipsilateral renal masses
- women who are pregnant or breastfeeding
- previous renal surgery that is expected to complicate renal cancer surgery
- cT ≥ 3
- planned off-clamp resection
- cognitive disorder which impedes with completing study questionnaires
Trial locations and contacts
5 sites in 1 country. Contact the study team or a site near you to ask about taking part.
5 sites in 1 country
Belgium5 sites, 5 recruiting
- Recruiting
AZORG
Aalst, 9300
Alexandre Mottrie, +3253724448, urologie.aalst@azorg.be
Alexandre Mottrie
- Recruiting
AZ Sint-Jan
Bruges, 8000
Christophe Ghysel, +3250452530, urologie@azsintjan.be
Christophe Ghysel
- Recruiting
ZOL
Genk, 3600
Bernard Bynens, +3289808380, secretariaat.urologie@zol.be
Bernard Bynens
- Recruiting
AZ Maria Middelares
Ghent, 9000
Karel Decaestecker, MD, PhD, +32 9 246 46 46, secretariaat.urologie@mijnziekenhuis.be
Karel Decaestecker, MD, PhD
- Recruiting
Ghent University Hospital
Ghent, 9000
Charles Van Praet, MD, PhD, +32 9 332 22 76, charles.vanpraet@uzgent.be
Charles Van Praet, MD, PhD
About this study
Official title: Planning Operative Strategy Using a Digital Renal Artery Clamping Tool: a Randomized Controlled Trial Evaluating the DIPLANN 3D Model for Selective Arterial Clamping During Robot-Assisted Partial Nephrectomy
A proposed new tool ('DIPLANN-tool' - Digital Planning in Nephrectomy) for predicting kidney perfusion zones on a segmented 3D model during robot-assisted partial nephrectomy (RAPN) for localized renal cancer demonstrated high accuracy when planning selective clamping (SC) for RAPN. However, the tool's clinical added value still needs to be confirmed. Therefore, a randomized controlled trial using a study and control group is the preferred study design.
Experimental group: the use of the DIPLANN-tool + conventional computed tomography (CT) imaging for preoperative planning and perioperative guidance during RAPN.
Read more
Control group: the use of only conventional CT imaging for preoperative planning and perioperative guidance during RAPN (= current standard of care).
The primary endpoint is planning and performing as planned a SC strategy. Secondary endpoints include patients' health, patients' insight and surgeons' benefits.
Read the detailed description
BACKGROUND:
For patients diagnosed with localized kidney cancer, two main options exist to surgically remove the kidney tumor. During radical nephrectomy (RN), the entire kidney is removed. During partial nephrectomy (PN), only the tumor is resected, safeguarding the function of the remaining healthy kidney tissue. This last procedure is preferred, but not always technically feasible. To resect only the tumor, a balance has to be found in the clamping approach: clamping the blood supply to the kidney assures bloodless tumor resection, yet compromises the postoperative renal function due to the temporary ischemia. Tumor resection without clamping on the other hand, might lead to substantial blood loss. That is why "selective clamping" (SC) is proposed. In this approach, only those selective arteries are clamped that perfuse the zone including the tumor. The main drawback of this strategy is that it is often not clear which arteries should be clamped based on standard preoperative imaging, while misjudgment can lead to a high-risk surgery with excessive bleeding or prolonged ischemia time. Therefore, RN is currently recommended when PN is considered not feasible. Better prediction of individual kidney perfusion will allow to perform more frequently a PN and thus save healthier kidney tissue. Additionally, it is difficult for patients to assess their own individual oncological situation based on 2D CT images.
With this project, the investigators want to offer the surgeon an easy-to-use virtual planning tool that facilitates the decision-making process regarding the feasibility of PN and the corresponding optimal clamping strategy. This tool uses virtual 3D models based on CT scans, to visualize precise information on the different anatomical structures and perfusion zones. This may also improve patients' understanding of their own individual situation. The proposed new tool (DIPLANN-tool) for predicting kidney perfusion zones on a segmented 3D model during robot-assisted partial nephrectomy (RAPN) for localized renal cancer demonstrated high accuracy when planning selective clamping (SC) for RAPN. However, the tool's clinical added value still needs to be confirmed. Therefore, a randomized controlled trial using a study and control group is the preferred study design.
DESIGN:
A confirmatory, multicentric, unblinded, randomized, controlled, pivotal trial using parallel group assignment and stratified randomization.
Experimental group: the use of the DIPLANN model + conventional CT imaging for preoperative planning and perioperative guidance.
Control group: the use of only conventional CT imaging for preoperative planning and perioperative guidance (= current standard of care).
METHODOLOGY:
Sample size calculation: 235 patients.
Patients will be randomized according to a 1:1 allocation ratio to either the experimental group (the DIPLANN-tool in combination with conventional CT imaging) or the control group (conventional CT imaging alone), using permuted block randomization with blocks of varying size.
Randomization will be stratified on the following variables:
- Whether SC is deemed possible according to the DIPLANN-tool in combination with conventional CT imaging or on conventional CT imaging alone, as assessed by an independent surgeon (between inclusion and randomization) who will not be not involved in the RAPN surgical procedure (yes vs no).
- Hospital where surgery is performed.
- PADUA classification (low (<8) and intermediate (8-9) vs high-risk (>9)). In case of multiple masses, the mass with the highest individual PADUA classification will be used.
PRIMARY OBJECTIVE:
To assess if the DIPLANN-tool in combination with conventional CT imaging is superior to conventional CT imaging alone, with respect to planning and performing as planned a SC strategy during RAPN, in patients diagnosed with localized kidney cancer who are planned to undergo renal cancer surgery and in whom SC is deemed possible either according to the DIPLANN-tool in combination with conventional CT imaging or according to conventional CT imaging only, as assessed between inclusion and randomization by an independent surgeon.
SECONDARY OBJECTIVES:
- To assess if the DIPLANN-tool in combination with conventional CT imaging is superior to conventional CT imaging alone, with respect to planning and performing as planned a SC strategy during RAPN, in patients diagnosed with localized kidney cancer who are planned to undergo renal cancer surgery.
- To compare the DIPLANN-tool in combination with conventional CT imaging to conventional CT imaging alone with respect to: patients' health, patients' insight, and surgeons' benefits.
ENDPOINTS:
The primary endpoint is planning and performing as planned a SC strategy. Secondary endpoints include patients' health, patients' insight and surgeons' benefits.
Extended listing of all outcome measures: see below.
- Conditions
- Kidney Cancer, Kidney Neoplasms, Kidney Diseases, Renal Cancer, Renal Cell Carcinoma, Renal Disease
- Being tested
- Pre-operative explanation of the procedure (DIPLANN + CT), Pre-operative surgical planning (DIPLANN + CT), RAPN (DIPLANN + CT), Pre-operative explanation of the procedure (CT only), Pre-operative surgical planning (CT only)
- Keywords
- Kidney Cancer, Renal Cell Carcinoma, Minimally Invasive Surgery, Robot-Assisted Surgery, Robot-Assisted Partial Nephrectomy, RAPN, 3D, Perfusion Zone
- Medical subject headings
- Kidney Neoplasms, Kidney Diseases, Carcinoma, Renal Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pre-operative explanation of the procedure (DIPLANN + CT)Device
Pre-operative study visit explaining the RAPN procedure using the 3D model / DIPLANN-tool (with or without classical CT imaging). Included in this visit is a pre-operative physical examination (height, weight, abdominal examination), pre-operative blood examination (Hb, creatinin, eGFR) and patient questionnaires regarding patient knowledge, patient anxiety and patient quality of life.
Pre-operative surgical planning (DIPLANN + CT)Device
Online assessment by surgeon regarding clamping strategy. Assisted by DIPLANN-tool + CT scan.
RAPN (DIPLANN + CT)Procedure or surgery
Robot-assisted partial nephrectomy surgical procedure. Peri-operative guidance by DIPLANN-tool + CT scan.
Pre-operative explanation of the procedure (CT only)Device
Pre-operative study visit explaining the RAPN procedure using CT imaging alone. Included in this visit is a pre-operative physical examination (height, weight, abdominal examination), pre-operative blood examination (Hb, creatinin, eGFR) and patient questionnaires regarding patient knowledge, patient anxiety and patient quality of life.
Pre-operative surgical planning (CT only)Device
Online assessment by surgeon regarding clamping strategy. Assisted by classical CT imaging only.
RAPN (CT only)Procedure or surgery
Robot-assisted partial nephrectomy surgical procedure. Peri-operative guidance by CT imaging only.
| Study group | Role | What they receive |
|---|---|---|
| DIPLANN-tool + conventional CT imaging | Experimental | Pre-operative planning and peri-operative guidance with DIPLANN-tool and conventional CT imaging. Receives: Device: Pre-operative explanation of the procedure (DIPLANN + CT); Device: Pre-operative surgical planning (DIPLANN + CT); Procedure: RAPN (DIPLANN + CT) |
| Conventional CT imaging alone | Active comparator | Pre-operative planning and peri-operative guidance with conventional CT imaging alone (standard of care). Receives: Device: Pre-operative explanation of the procedure (CT only); Device: Pre-operative surgical planning (CT only); Procedure: RAPN (CT only) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Selective clamping
Planning and performing as planned a selective clamping (SC) strategy (considered by the surgeon at the end of surgery, objectified pre- and postoperatively through online assessment on study website and controlled through video-analysis): planning SC and performing the planned SC strategy = positive outcome; planning SC and performing another SC strategy or full clamping (FC) = negative outcome; planning FC = negative outcome.
Measured: During surgery
Secondary outcomes (4)
eGFR 6 months
Change in eGFR at 6 months after surgery compared to eGFR preoperatively.
Measured: 6 months postoperatively
Clamping strategy
Clamping strategy performed (selective clamping or full clamping).
Measured: During surgery
Hilar dissection time
Time to dissect hilum (minutes) as analyzed on postoperative surgical video analysis.
Measured: During surgery
Conversion to full clamp
Conversion from SC to FC.
Measured: During surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Aug 2024
- Study start27 Jun 2024
- Primary completion1 Jan 2027 (estimated)
- Study completion1 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Kidney CancerStudies of the same condition, open and under way.
- More trials run by University Hospital, GhentThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Confirmatory, multicentric, unblinded, randomized, controlled, pivotal trial using parallel group assignment and stratified randomization.
- Masking
- None (open label)
- Enrolment
- 235 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Ghent
- Sponsor type
- University, hospital or other
- Collaborators
- Stichting tegen Kanker, University Ghent
- Responsible party
- Sponsor
- Investigators
- Charles Van Praet, MD, PhD, Principal investigator, University Hospital, Ghent
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06536439
- Sponsor's protocol ID
- ONZ-2023-0558
- Acronym
- PODRACING
- Status last verified
- Mar 2025
- First submitted
- 15 Jul 2024
- Last updated
- 1 Apr 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Vangeneugden J, Vermijs S, De Backer P, Berquin C, Lumen N, De Kuyper P, Raskin Y, Bynens B, Baekelandt F, Ghysel C, Peeren F, De Groote R, De Naeyer G, Mottrie A, De Buyser S, De Visschere P, Debbaut C, Decaestecker K, Van Praet C. Clinical trial protocol of PODRACING: A randomized controlled trial evaluating 3D perfusion zone models for selective arterial clamping during robot-assisted partial nephrectomy. BJUI Compass. 2026 Mar 30;7(4):e70191. doi: 10.1002/bco2.70191. eCollection 2026 Apr.
PubMed 42022229Vangeneugden J, Vermijs S, De Backer P, Hemeryck B, Berquin C, De Visschere P, Decaestecker K, Debbaut C, Van Praet C. Three-dimensional Perfusion-zone Models Allow More Selective Clamping During Robot-assisted Partial Nephrectomy: Brief Report on a Retrospective Analysis. Eur Urol Open Sci. 2025 Nov 5;82:128-130. doi: 10.1016/j.euros.2025.10.013. eCollection 2025 Dec.
PubMed 41280160
Study at a glance
From the registry record, last updated by the sponsor on 1 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Planning Operative Strategy Using a Digital Renal Artery Clamping Tool: a Randomized Controlled Trial Evaluating the DIPLANN 3D Model for Selective Arterial Clamping During Robot-Assisted Partial Nephrectomy
- ClinicalTrials.gov ID
- NCT06536439
- Acronym / sponsor ID
- PODRACING / ONZ-2023-0558
- Conditions
- Kidney Cancer, Kidney Neoplasms, Kidney Diseases, Renal Cancer, Renal Cell Carcinoma, Renal Disease
- Keywords
- Kidney Cancer, Renal Cell Carcinoma, Minimally Invasive Surgery, Robot-Assisted Surgery, Robot-Assisted Partial Nephrectomy, RAPN, 3D, Perfusion Zone
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 235 participants (estimated)
- Lead sponsor
- University Hospital, GhentUniversity, hospital or other
- Collaborators
- Stichting tegen Kanker, University Ghent
- Study start
- 27 Jun 2024 (actual)
- Primary completion
- 1 Jan 2027 (estimated)
- Study completion
- 1 Jan 2027 (estimated)
- First posted
- 5 Aug 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A proposed new tool ('DIPLANN-tool' - Digital Planning in Nephrectomy) for predicting kidney perfusion zones on a segmented 3D model during robot-assisted partial nephrectomy (RAPN) for localized renal cancer demonstrated high accuracy when planning selective clamping (SC) for RAPN. However, the tool's clinical added value still needs to be confirmed. Therefore, a randomized controlled trial using a study and control group is the preferred study design.
Experimental group: the use of the DIPLANN-tool + conventional computed tomography (CT) imaging for preoperative planning and perioperative guidance during RAPN.
Control group: the use of only conventional CT imaging for preoperative planning and perioperative guidance during RAPN (= current standard of care).
The primary endpoint is planning and performing as planned a SC strategy. Secondary endpoints include patients' health, patients' insight and surgeons' benefits.
Detailed description
BACKGROUND:
For patients diagnosed with localized kidney cancer, two main options exist to surgically remove the kidney tumor. During radical nephrectomy (RN), the entire kidney is removed. During partial nephrectomy (PN), only the tumor is resected, safeguarding the function of the remaining healthy kidney tissue. This last procedure is preferred, but not always technically feasible. To resect only the tumor, a balance has to be found in the clamping approach: clamping the blood supply to the kidney assures bloodless tumor resection, yet compromises the postoperative renal function due to the temporary ischemia. Tumor resection without clamping on the other hand, might lead to substantial blood loss. That is why "selective clamping" (SC) is proposed. In this approach, only those selective arteries are clamped that perfuse the zone including the tumor. The main drawback of this strategy is that it is often not clear which arteries should be clamped based on standard preoperative imaging, while misjudgment can lead to a high-risk surgery with excessive bleeding or prolonged ischemia time. Therefore, RN is currently recommended when PN is considered not feasible. Better prediction of individual kidney perfusion will allow to perform more frequently a PN and thus save healthier kidney tissue. Additionally, it is difficult for patients to assess their own individual oncological situation based on 2D CT images.
With this project, the investigators want to offer the surgeon an easy-to-use virtual planning tool that facilitates the decision-making process regarding the feasibility of PN and the corresponding optimal clamping strategy. This tool uses virtual 3D models based on CT scans, to visualize precise information on the different anatomical structures and perfusion zones. This may also improve patients' understanding of their own individual situation. The proposed new tool (DIPLANN-tool) for predicting kidney perfusion zones on a segmented 3D model during robot-assisted partial nephrectomy (RAPN) for localized renal cancer demonstrated high accuracy when planning selective clamping (SC) for RAPN. However, the tool's clinical added value still needs to be confirmed. Therefore, a randomized controlled trial using a study and control group is the preferred study design.
DESIGN:
A confirmatory, multicentric, unblinded, randomized, controlled, pivotal trial using parallel group assignment and stratified randomization.
Experimental group: the use of the DIPLANN model + conventional CT imaging for preoperative planning and perioperative guidance.
Control group: the use of only conventional CT imaging for preoperative planning and perioperative guidance (= current standard of care).
METHODOLOGY:
Sample size calculation: 235 patients.
Patients will be randomized according to a 1:1 allocation ratio to either the experimental group (the DIPLANN-tool in combination with conventional CT imaging) or the control group (conventional CT imaging alone), using permuted block randomization with blocks of varying size.
Randomization will be stratified on the following variables:
- Whether SC is deemed possible according to the DIPLANN-tool in combination with conventional CT imaging or on conventional CT imaging alone, as assessed by an independent surgeon (between inclusion and randomization) who will not be not involved in the RAPN surgical procedure (yes vs no).
- Hospital where surgery is performed.
- PADUA classification (low (<8) and intermediate (8-9) vs high-risk (>9)). In case of multiple masses, the mass with the highest individual PADUA classification will be used.
PRIMARY OBJECTIVE:
To assess if the DIPLANN-tool in combination with conventional CT imaging is superior to conventional CT imaging alone, with respect to planning and performing as planned a SC strategy during RAPN, in patients diagnosed with localized kidney cancer who are planned to undergo renal cancer surgery and in whom SC is deemed possible either according to the DIPLANN-tool in combination with conventional CT imaging or according to conventional CT imaging only, as assessed between inclusion and randomization by an independent surgeon.
SECONDARY OBJECTIVES:
- To assess if the DIPLANN-tool in combination with conventional CT imaging is superior to conventional CT imaging alone, with respect to planning and performing as planned a SC strategy during RAPN, in patients diagnosed with localized kidney cancer who are planned to undergo renal cancer surgery.
- To compare the DIPLANN-tool in combination with conventional CT imaging to conventional CT imaging alone with respect to: patients' health, patients' insight, and surgeons' benefits.
ENDPOINTS:
The primary endpoint is planning and performing as planned a SC strategy. Secondary endpoints include patients' health, patients' insight and surgeons' benefits.
Extended listing of all outcome measures: see below.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Confirmatory, multicentric, unblinded, randomized, controlled, pivotal trial using parallel group assignment and stratified randomization.
| Arm | Type | Receives |
|---|---|---|
| DIPLANN-tool + conventional CT imaging | Experimental | Device: Pre-operative explanation of the procedure (DIPLANN + CT), Device: Pre-operative surgical planning (DIPLANN + CT), Procedure: RAPN (DIPLANN + CT)Pre-operative planning and peri-operative guidance with DIPLANN-tool and conventional CT imaging. |
| Conventional CT imaging alone | Active comparator | Device: Pre-operative explanation of the procedure (CT only), Device: Pre-operative surgical planning (CT only), Procedure: RAPN (CT only)Pre-operative planning and peri-operative guidance with conventional CT imaging alone (standard of care). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- aged 18 years or above
- cT1-2 N0 M0 renal mass
- planned to undergo RAPN
- multiphase CT scan with arterial phase available
- voluntary given and written informed consent
Key exclusion criteria (6 listed)
- > 3 ipsilateral renal masses
- women who are pregnant or breastfeeding
- previous renal surgery that is expected to complicate renal cancer surgery
- cT ≥ 3
- planned off-clamp resection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pre-operative explanation of the procedure (DIPLANN + CT)Pre-operative study visit explaining the RAPN procedure using the 3D model / DIPLANN-tool (with or without classical CT imaging). Included in this visit is a pre-operative physical examination (height, weight, abdominal examination), pre-operative blood examination (Hb, creatinin, eGFR) and patient questionnaires regarding patient knowledge, patient anxiety and patient quality of life. | Device | DIPLANN-tool + conventional CT imaging |
| Pre-operative surgical planning (DIPLANN + CT)Online assessment by surgeon regarding clamping strategy. Assisted by DIPLANN-tool + CT scan. | Device | DIPLANN-tool + conventional CT imaging |
| RAPN (DIPLANN + CT)Robot-assisted partial nephrectomy surgical procedure. Peri-operative guidance by DIPLANN-tool + CT scan. | Procedure or surgery | DIPLANN-tool + conventional CT imaging |
| Pre-operative explanation of the procedure (CT only)Pre-operative study visit explaining the RAPN procedure using CT imaging alone. Included in this visit is a pre-operative physical examination (height, weight, abdominal examination), pre-operative blood examination (Hb, creatinin, eGFR) and patient questionnaires regarding patient knowledge, patient anxiety and patient quality of life. | Device | Conventional CT imaging alone |
| Pre-operative surgical planning (CT only)Online assessment by surgeon regarding clamping strategy. Assisted by classical CT imaging only. | Device | Conventional CT imaging alone |
| RAPN (CT only)Robot-assisted partial nephrectomy surgical procedure. Peri-operative guidance by CT imaging only. | Procedure or surgery | Conventional CT imaging alone |
Primary outcome
Selective clamping
Time frame: During surgery
Planning and performing as planned a selective clamping (SC) strategy (considered by the surgeon at the end of surgery, objectified pre- and postoperatively through online assessment on study website and controlled through video-analysis): planning SC and performing the planned SC strategy = positive outcome; planning SC and performing another SC strategy or full clamping (FC) = negative outcome; planning FC = negative outcome.
4 secondary outcomes
eGFR 6 months
Time frame: 6 months postoperatively
Clamping strategy
Time frame: During surgery
Hilar dissection time
Time frame: During surgery
Conversion to full clamp
Time frame: During surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Apr 2025.
- Derived from this study: PubMed 42022229Vangeneugden J, Vermijs S, De Backer P, Berquin C, Lumen N, De Kuyper P, Raskin Y, Bynens B, Baekelandt F, Ghysel C, Peeren F, De Groote R, De Naeyer G, Mottrie A, De Buyser S, De Visschere P, Debbaut C, Decaestecker K, Van Praet C. Clinical trial protocol of PODRACING: A randomized controlled trial evaluating 3D perfusion zone models for selective arterial clamping during robot-assisted partial nephrectomy. BJUI Compass. 2026 Mar 30;7(4):e70191. doi: 10.1002/bco2.70191. eCollection 2026 Apr.
- Derived from this study: PubMed 41280160Vangeneugden J, Vermijs S, De Backer P, Hemeryck B, Berquin C, De Visschere P, Decaestecker K, Debbaut C, Van Praet C. Three-dimensional Perfusion-zone Models Allow More Selective Clamping During Robot-assisted Partial Nephrectomy: Brief Report on a Retrospective Analysis. Eur Urol Open Sci. 2025 Nov 5;82:128-130. doi: 10.1016/j.euros.2025.10.013. eCollection 2025 Dec.
- Individual participant dataSharing planned: No
Related trials for Kidney Cancer
RecruitingObservational study
Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer
Kidney Neoplasms, Kidney Cancer
RecruitingObservational study
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
Pheochromocytoma, Paraganglioma
Active, not recruitingPhase 1/2
Study of ST-1898 in Advanced Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
Active, not recruitingPhase 1/2
Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Active, not recruitingPhase 1
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
Breast Cancer, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Charles Van Praet, MD, PhD principal investigator
University Hospital, Ghent
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Pre-operative explanation of the procedure (DIPLANN + CT), Pre-operative surgical planning (DIPLANN + CT) and RAPN (DIPLANN + CT) in people with Kidney Cancer and Kidney Neoplasms, run by University Hospital, Ghent at 5 sites in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 1 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Joris Vangeneugden, MD (+32 9 332 22 76, joris.vangeneugden@ugent.be), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Selective clamping (time frame: During surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06536439, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Apr 2025.